 |
News
-
IGBA Statement on trade barriers and their impact on healthcare systems and patients’ health (March 2025)
The International Generic and Biosimilar medicines Association (IGBA) remains committed to its vision of working to improve patient access to safe, effective, cost-effective, and quality-assured generic and biosimilar medicines.
Read More -
Harmonising Bioequivalence: Advancing Global Access to Generic Medicines (February 2025)
The 3rd Bioequivalence Conference, co-hosted by the International Generic and Biosimilar Medicines Association (IGBA) and Medicines for Europe, concluded today at the Hilton Amsterdam Airport Schiphol Hotel, The Netherlands. This landmark event brought together experts from regulatory authorities, industry, and
… Read More -
IGBA releases first global Intellectual Property and Competition Report (February 2025)
The International Generic and Biosimilar Medicines Association (IGBA) in line with its goals of promoting the widest possible access to safe, effective, and quality-assured medicines; and of promoting intellectual property regimes which foster innovation and allow the timely entry of
… Read More -
Joint Industry Statement for WHO's Executive Board Meeting 156 (February 2025)
The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), Global Diagnostic Imaging, Healthcare IT & Radiation Therapy Trade Association (DITTA), Global Self-Care Federation (GSCF), International Pharmaceutical Federation (FIP), International Alliance of Patients’ Organizations (IAPO), and International Generic and Biosimilar Medicines
… Read More -
IGBA welcomes new chair and new full member (January 2025)
IGBA, the International Generic and Biosimilar Medicines Association (IGBA) , representing global manufacturers of generic and biosimilar medicines, announced today that Shinichiro Hirose, Director of International Affairs at the Japanese Generic Medicines Association (JGA) is taking over the position of IGBA
… Read More -
Lucas Sigman and Allan Oberman appointed 2025 Chair and Vice-Chair of the IGBA CEO Advisory Committee (December 2024)
The International Generic and Biosimilar medicines Association (IGBA) announced today the annual leadership change of its CEO Advisory Committee (AC). Lucas Sigman, CEO of Insud Pharma, has been appointed Chair and Allan Oberman, President and CEO of Apotex, Vice-Chair.
Read More -
INC-5 opening statement: Health industry support for a plastics instrument (November 2024)
25 NOVEMBER 2024, BUSAN, SOUTH KOREA – This statement is delivered on behalf of IFPMA, GSCF, and IGBA, who collectively represent innovative, generic, and biosimilars pharmaceutical companies, as well as consumer healthcare manufacturers.
Read More -
High-Level Statement: Comprehensive approach for a treaty to end plastics pollution: Perspectives from the biopharmaceutical and consumer health industries (November 2024)
14 NOVEMBER 2024, GENEVA – We support a UN instrument to end plastics pollution through a harmonized, global approach that also prioritizes patient safety and safeguards access to medicinal and medical products.
Read More -
Global Biosimilars Week 2024 to Focus on Advancing Access to Biosimilars (November 2024)
In the week ahead, the International Generic and Biosimilar medicines Association (IGBA) will renew its commitment to raise awareness of the powerful and lifechanging impact of biosimilar medicines, and focus on the importance of advancing access to these essential therapies.
Read More -
AMIP, the Moroccan Pharmaceutical Industry Association, joins IGBA (September 2024)
IGBA, the International Generic and Biosimilar medicines Association, representing global manufacturers of generic and biosimilar medicines, announced today that AMIP has been accepted and welcomed as a new IGBA Associate Member.
Read More -
IGBA identifies streamlined development through reduced comparative clinical studies and appropriate use of global comparator product as key to greater biosimilar access (July 2024)
The mandate to conduct routine comparative clinical efficacy studies for biosimilar medicines, compounded by duplicative regional requirements, serves as a barrier to greater medicine access for patients. The International Generic and Biosimilar Medicines Association (IGBA) has issued two position papers;
… Read More -
IGBA Statement at the Opening of the Sessions at the WIPO Assemblies (July 2024)
Pharmaceutical innovation drives progress, and deserves reward, with intellectual property playing a key role in its protection. Expanding access to these innovations after rewarding them is crucial for public health. In well-functioning markets, generic and biosimilar medicines provide affordable, quality-assured
… Read More
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
Our Mission and Vision
Our vision is to promote the widest possible access to generic and biosimilar medicines with high quality, safety and efficacy, support international harmonized pathways for the registration of those medicines, and a strong commitment by members to standards agreed by the International Council for Harmonization (ICH) and WHO accredited regulators.
Introduction
In an era when increasing demands are being made on the world’s healthcare services, generic and biosimilar medicines provide a major benefit to society by ensuring patient access to quality, safe and effective medicines while reducing the cost of pharmaceutical care.
The International Generic Pharmaceutical Alliance (IGPA) was founded in March 1997 as an international network of generic medicines associations. To reflect the evolving nature of the industry, in September 2015, IGPA incorporated under Swiss Law, and at the same time changed the name of the organization to the International Generic and Biosimilar Medicines Association (IGBA).
